SUBJECT INDEX: VOLUME 42 (2002)

In the subject index, the page number refers to the first page of the communication in which the subject is addressed rather than to the specific page on which the referenced key words can be found. An "L" in parentheses following the page number indicates that the subject entry appeared in a letter to the editor; an 'E" in parentheses indicates that the subject was discussed in an editorial; a "/" between numbers indicates on what page the correction for the subject entry appears.

In Volume 42 (2002), Number One (January) contains pages 1-134; Number 2 (February), pages 135-278; Number 3 (March), pages 279-386; Number 4 (April), pages 387-508; Number 5 (May), pages 509-662; Number 6 (June), pages 663-808; Number 7 (July), pages 809-964; Number 8 (August), pages 965-1104; Number 9 (September), pages 1105-1244; Number 10 (October), pages 1245-1388; Number 11 (November), pages 1389-1530; and Number 12 (December), pages 1531-1640.

A

ABO blood group
- bedside testing, reliability of ... 1238(L), 1348
- blood transfusion mismatch ... 205
- chimerism detection/quantification ... 702
- *cis AB.tise*01* allele ... 239
- enzymatic removal of A antigen, immunologic properties of RBCs after ... 662(C)
- maternofetal transfusion, gel-based typing detection of ... 1531
- minor-mismatched PBPC grafts, hemolysis after ... 1293
- novel *A* allele at *ABO* locus ... 294
- platelet transfusion mismatch ... 166, 1527(L)
- UV-visible spectrophotometric typing ... 619

ACD-A solution, ionized calcium stabilization and ... 1340
Activated platelets, in vivo binding to WBCs after transfusion ... 1373
Acute chest syndrome, human polymerized Hb solution for ... 1422
ADAMTS13 deficiency, thrombotic thrombocytopenic purpura and ... 1523(L)
Additive solutions, effects on magnesium and/or potassium ... 76
Age
- CD34+ cell collection and ... 4
- spinal surgery transfusion outcome and ... 183

Albumin transfusion, pediatric guidelines ... 1398
Allogeneic blood transfusion
- outcome predictors ... 183
- postoperative pneumonia and/or wound infection and ... 107

Alloimmunization
- phenotype-matched transfusions in sickle cell disease and ... 684
- in sickle cell disease ... 37

AmpliScreen test methods, for HIV and HCV NAT minipool screening ... 792
Anaphylactic reaction, in haptoglobin-deficient patient ... 766
Anaplasma phagocytophila seroprevalence, tick bites and ... 1585
Anemia
- autoimmune hemolytic anemia ... 567, 1390(E), 1345
- in AIDS patients, due to parvovirus B19 ... 1
- iron deficiency, in female blood donors ... 798
- microangiopathic hemolytic, due to mitral valve ... 1105
- unexplained ... 1610
- WBC-reduced RBCs *vs.* non-WBC-reduced RBCs for ... 265

Animal models, of transmissible spongiform encephalopathies ... 334, 509(E), 513, 517
Anticoagulant
- ACD-A solution, ionized calcium stabilization and ... 1340
- RBC damage during blood collection and ... 343

Anti-D absence of, after D-incompatible platelet transfusion ... 136(E), 173, 177, 1618
Antigen-matched donor blood
- for patients with sickle cell disease ... 658(L)
- for warm autoantibodies prophylaxis ... 1435

Anti-HBc nucleic acid testing ... 869
Anti-HBc-positive donors with HBsAg-negativity ... 1616(L)
Anti-HCV screening
- immunoblot assay sensitivity ... 1053
- lookback program ... 1501
- lookback program in England ... 1140

Anti-IFC ... 1448
Anti-Jk^a ... 363
Anti-Lu6 ... 247
Antiplasmin viability, in thawed S/D-treated plasma ... 1581
Anti-Vel reactivity ... 1180
Apoptosis
- cellular prion protein ... 334, 509(E), 513, 517
- immunosuppressive transfusion effect and ... 1221

Aspirin-induced thrombocytopathy, fresh and preserved platelets for ... 1206
Atherosclerosis, iron lowering by blood donation and ... 1135
ATP in RBCs, alkaline conditions and ... 747
Attitudinal factors, in blood donation ... 669
Australia, risk modeling in ... 1365
Autoantibodies, in sickle cell disease ... 37
Autoimmune hemolytic anemia
- blood transfusion selection approaches ... 1390(E), 1345
- DPT vaccination as trigger for ... 567

Autologous blood donation, preoperative
- declining value of ... 819, 1618(C)
- in Europe ... 1614(L), 1615(L)

Autologous transfusion
- for GVHD ... 1567
- pediatric guidelines ... 1398
- recovery, composition of leukapheresis components and ... 1159
- of WBC-reduced platelet concentrates, recovery from ... 1333

Automated systems
- for chemiluminescent HCV core antigen immunoassay ... 349
- for nucleic acid detection system ... 100
- for platelet component bacterial culturing ... 774
- A-zyme, effect on immunologic properties of RBCs ... 662(C)

B

Babesia microti
- antibody identification methods ... 1488
- morphology ... 1389
- seroprevalence in blood donors, tick bites and ... 1585
- transfusion-associated transmission ... 1154, 1482

Bacterial contamination
- automated system for screening platelets ... 774
- of blood components ... 380(L)
- universal culturing method for apheresis platelet units ... 855

Basic fibroblast growth factor, for stem cell expansion ... 921
Bedside testing of ABO blood group ... 1238(L)
Bleeding time, hetastarch *vs.* pentastarch ... 27
Blood collection
- RBC damage, effect of anticoagulant and blood pH on ... 343
- in US in 1997 ... 1253
- in utero *vs.* ex utero cord blood ... 1281

Blood components. *See also specific blood components*
- glucan in, depth-type filters and ... 1189
- prestorage temperature, for *Yersinia enterocolitica* load reduction ... 422

Blood donation. *See also* Donors
- allogeneic PBPC, citrate and calcium effects in ... 935
- autologous blood ... 1618(C)
- *Babesia microti* transmission ... 1154
- HCV nosocomial infection detected by NAT ... 759
- iron depletion after ... 664(E), 799
- iron lowering, cardiovascular risk and ... 1135
- maintaining iron balance in female donors ... 798
- motivations, demographic comparisons of ... 216
- nucleic acid testing ... 1230
- perceived HIV infection risk and ... 679
- preoperative autologous ... 819, 1614(L), 1615(L)
- sociodemographic, medical and attitudinal factors in ... 669
- specificity for HIV antibody testing for ... 1046
- vasovagal reactions to ... 1534(E), 1557

Blood group typing
gel-based, detection of maternofetal transfusion 1531
UV-visible spectrophotometric 619
Blood salvage, intraoperative 451
Blood storage. *See* Storage
Blood storage bags
physical and thermal properties 836
plasticizer effect on RBCs 830
Blood supply
PEN110 pathogen decontamination for 139
September 11, 2001 disaster and ..... 1240(L), 1385(L)
vasovagal donor reactions and ..... 1534(E), 1557
Blood transfusion
pediatric ..... 666(E), 754, 1398, 1482
refusal for religious reasons 812
selection approaches for autoimmune hemolytic anemia ..... 1390(E), 1345
in US in 1997 1253
West Nile virus transmission and 1019
xenogeneic ..... 1111(E), 1184
Bovine spongiform encephalopathy ..... 334, 509(E), 513, 517
Bovine thrombin exposure, FV inhibitors and 18
Bradykinin, hypotension during Staphylococcal protein therapy 1458
Brain and buffy coat transmission, of bovine spongiform encephalopathy ..... 509(E), 513

C

Calcium, effects in leukapheresis 935
Cardiovascular risk, low iron levels and 1135
Cardiovascular surgery
ABO-nonidentical platelet transfusions for ..... 166, 1527(L)
outcomes, after ABO-mismatch platelet transfusions ..... 1527(L)
postoperative infection rates, WBC reduction and ..... 1106(E), 1127
CD34+ cells
collection, yield prediction for 4
composition of leukapheresis components, mobilization regimen and 1159
concentration during PBPC collection 904
enumeration before apheresis, predictive value of 1514
immunomagnetic selection in closed-bag system 1285
isolation and B cell reduction from peripheral blood 912
CD55 deficiency, anti-IFC and 1448
CD36 isoimmunization 1173
Cell selection, positive-negative magnetic 912
Cell separators, comparison of 375
Cerebrovascular nodules, with leukostasis 965
Cesarean section delivery, WBC yield from cord blood units and 210
Chagas' disease, in blood donors 549
Chemiluminescent immunoassay
automated, for HCV core antigen 349
for HBV and HCV 100
Chemotherapy-induced mobilization, predictive value of CIC for PBPC collection 1514
platelet count recovery prediction, reticulated platelets and 368
Childhood TT virus infection 892
Chimerism
ABO RBC, detection/quantification by modified coil planet centrifuge method 702
xenogeneic ..... 1111(E), 1184
Circulating immature cell counts, predictive value 1514
Citrate, effects in leukapheresis 935
CJD
animal models ..... 334, 509(E), 513, 517
prion protein expression, comparative analysis of 517
Clinical studies, integrating with molecular studies ..... 284(E), 287
Clotting factor concentrates
heat-treated, parvovirus B19 transmission and 1473
pediatric transfusion guidelines 1398
CMV
efficacy of WBC reduction in neonates 159
in RBC units, quantitation by real-time PCR 403
transfusion-acquired infection, risk of 396
transmission prevention, pediatric guidelines for 1398
Coil planet centrifuge method 702
Consent, for cord blood donation ..... 1246(E), 1268
Cord blood
antibody detection, gel microcolumn assay for 698
banking ..... 1246(E), 1275
consent policy for collection 1268, 1275
donors, racial makeup of vs. unrelated marrow donors 1279
in utero or ex utero collection 1261
CD34+ cells immunomagnetic selection in closed-bag system 1285
cultured with AB serum-based medium for stem cell expansion 921
non-frozen preservation of ..... 1383(L)
pediatric transfusion guidelines for 1398
Cord blood collection
mode of birth influence on 210
in utero *vs.* ex utero 1281
Cord blood donors
phased consent policy ..... 1246(E), 1268
racial/ethical composition of ..... 1246(E), 1279
Coronary artery bypass graft surgery
allogeneic plasma exposure, infection risk and 107
hospital costs, impact of WBC reduction on ..... 1106(E), 1123
Coronary artery disease rates, iron lowering by blood donation and 1135
Cryoprecipitate transfusion, pediatric guidelines 1398
Cryopreserved platelets, for aspirin-induced thrombocytopathy 1206
Culture methods
automated, for platelet components 774
to detect apheresis platelet unit contamination 855

D

D alloimmunization, absence in D– platelet transfusion 177
D monoclonal antibodies 59
D– patients, immunoprophylaxis for ..... 136(E), 173, 177, 1618(C)
D phenotype, novel partial 481
Delayed hemolytic transfusion reaction, in vitro hemolysis after 1086
Demographics
of blood donors, *Trypanosama cruzi* seroprevalence and 549
donation motivations and 216
Dendritic cell vaccination therapy, autologous monocyte collection for 428
Des-ARG^9-bradykinin, hypotension during Staphylococcal protein A therapy and 1458
Dexamethasone
in G-CSF granulocyte mobilization, kinetics of 597
with lenograstim for granulocyte mobilization and collection 928
D(C)(e) haplotypes, in white population 627
Diabetes mellitus, outcome for spinal surgery transfusions 183
Diamond, Louis K. 1381
Diego blood group, DNA-based genotyping 1553
Di(2-ethyl)hexylphthalate, effect on stored RBCs 830
D-incompatible platelet transfusions, absence of anti-D after ..... 136(E), 173, 177, 1618(C)
Dimethylmethylene blue phototreatment, flow-cell system for 1200
Dipyridamole, for RBC protection 728
Direct viral detection assays, residual risk of HCV and HIV infections ..... 966(E), 989
DMSO, use in HPC preservation and transplantation to children ..... 962(L)
DNA detection
HBV and HCV 100
Treponema pallidum 94
DNA genotyping
motherless cases 954
for multiply-transfused sickle cell patients 232
Dogs, *Leishmania donovani* transmission via transfusion ..... 381(L)
Dombrock blood group system, phenotypic relationships in 52
Donors
Australian, residual risk in 1365
combined malaria antibody and antigen screening for 357
DNA-based genotype screening 1553
female 669, 798

HBsAg-negative anti-HBc-positive, HBV DNA in ..... 1616(L)
HIV seroconverting, delayed return of 414
prevalence/incidence of infectious disease markers in . 966(E), 975
race/ethnicity and recruitment of vs. marrow donors ..... 1246(E), 1279
simian foamy virus infection in 886
tick bites, seroprevalence of tick-borne diseases and 1585
Trypanosoma cruzi-seropositive 549
vasovagal reactions ..... 1534(E), 1557
viral marker rates before/after Sept. 11, 2001 ..... 1240(L), 1385(L)
2,3-DPG
Erythro-Sol 2 and 824
preservation, alkaline CPD and 747
DPT vaccination, as autoimmune hemolytic anemia trigger 567
Dried plasma spots method, for RNA stabilization 409
DTI phenotype 481

E

EDTA-anticoagulated blood, hemolysis after delayed hemolytic transfusion reaction 1086
EIA
Babesia microti antibody detection 1488
HCV RNA testing compared to ELISA 1507
specificity for HIV antibodies 1046
Elastic properties, of irradiated RBCs 1196
ELISA
Babesia microti antibody detection 1488
HCV core antigen detection ..... 505(L), 1037
HCV RNA testing compared to EIA 1507
for HTLV-I and HTLV-II diagnosis 780
with immunofluorescent antibody test for malaria detection ... 357
Endemic areas, HBV transfusion-transmitted infections in 1592
Endothelial cells, cellular prion protein expression ..... 334, 509(E), 513, 517
England, HCV lookback program 1140, 1146
Engraftment in multiple myeloma, ABO mismatch and 205
Enterovirus, removal by nanofiltration ..... 973(E), 1005
Enzyme treatment, for RBC adherence assay 476
Errors in transfusion ..... 1238(L)
Erythromelalgia, due to essential thrombocythemia 1245
Erythro-Sol 2, for improved RBC storage 824
Essential thrombocythemia, erythromelalgia of 1245
Ethics, phased consent policy for cord blood donation ..... 1246(E), 1268
Ethnicity
of cord blood donors ..... 1246(E), 1279
RHC and *RHc* genotyping 634
Europe
HCV and HIV-1 yield after NAT screening 862
preoperative autologous blood donation ..... 1614(L), 1615(L)
Evidence-based clinical reporting ..... 1106(E), 1114, 1123, 1127

F

F(ab), dimeric 257
FV inhibitors, bovine thrombin exposure and 18
FV viability, in thawed S/D-treated plasma 1581
FVII
acqured deficiency, rFVIIa for 114
congenital deficiency, rFVIIa for 114
pharmacokinetics after warfarin treatment 1302
FVIII, viability in thawed S/D-treated plasma 1581
FVIII inhibitors in hemophilia, rFVIIa for 114
F IX concentrates, plasma-derived and recombinant, pharmacokinetic analysis of 190
F IX inhibitors in hemophilia, rFVIIa for 114
Family study, of DTI phenotype 481
Fat particles, detection/removal in salvaged blood 66
FCGR3 variants, in northern Germany and Uganda populations 469
Fear of hospitals, blood donation and 669
Female blood donors 669, 798
Fetomaternal hemorrhage
quantitation by fluorescence microscopy 947
semiautomated flow cytometric analysis of 1067
FFP
as by-product of plateletpheresis 81
pediatric transfusion guidelines 1398
psoralen plus UV-treated 1302
Filters
depth-type, glucan in blood components and 1189
in-line 734
sickle Hb polymerization causing RBC filter failures 1466
soft-shell 153
Filtration, blood. *See also* WBC reduction
fat particle removal in salvaged blood 66
prestorage WBC filtration of RBC units 153
quantitation of residual WBCs after 87
Flow cytometry
HNA-2a expression in Japanese 651
monocyte phagocytic assay 309
semiautomated, of fetomaternal hemorrhage in D^- women .. 1067
in vivo viability of platelet concentrates in rabbit model 711
vs. gel centrifugation test for IgG quantification 612
Flow-cell system, for dimethylmethylene blue phototreatment 1200
France
hemovigilance network in ..... 1249(E), 1356
transfusion-transmitted viral infections in ..... 966(E), 980
Fructose diphosphate in RBC preservation ..... 384(L)
Functional status and transfusion trigger for HIV-infected patients .. 456

G

α-Galactosyl expression, in pigs ..... 1111(E), 1184
α(1,4)Galactosyltransferase gene 48
Gamma irradiation, *vs.* PEN 110 for WBC reduction 1318
Gating strategy, with daily run control for standardizing WBC counting 738
G-CSF granulocyte mobilization
characterization/functional analysis of granulocyte concentrates from 603
down modulation of PSGL-1 328
kinetics of 597
MMP-9 elevation during 588
plus dexamethasone 928
predictive value of circling immature cells for PBPC collection 1514
in vitro safety profile 433
Gel centrifugation test, IgG antibodies and subclasses 612
Gel microcolumn assay, for antibodies in acid eluates 698
Gel-based typing, for maternofetal transfusion 1531
Gender, outcome for spinal surgery transfusions and 183
Genetic disorders, transmission risk in hematopoietic stem cell transplantation 495
Genotyping
DNA-based for screening Di(b–) blood donors 1553
of human platelet antigens, with simultaneous PCR 1089
motherless cases 954
for multiply-transfused sickle cell patients 232
noninvasive fetal *RHD* 1079
Glucan, in blood components, depth filters and 1189
Glucose reagent strip, detection of bacteria in platelet concentrates 1027
Glycoprotein IV, isoimmunization 1173
Good Manufacturing Practice, contamination of progenitor cell components or collections and 10
Granulocyte alloantigen nomenclature, standardization of ..... 3393(E), 469, 1396(E), 1523(L)
Granulocyte concentrates 603
Granulocyte Immunology Workshop, Fourth International 462
Granulocyte mobilization, kinetics of 597
Granulocyte transfusions
for infections in HPC transplantation ..... 1393(E), 1414
pediatric guidelines 1398
re-examination of ..... 1393(E), 1414
Griffonia simplicifolia IB4 lectin ..... 806(L)
GVHD
early diagnosis and treatment with autologous PBPC transplantation 1567

murine, PEN110 inhibition of 1326
prevention, pediatric guidelines for 1398

H

Haptoglobin deficiency and antibodies 766
HAV nucleic acid testing 1230
Hb
human polymerized, for acute chest syndrome 1422
nitric oxide transport/delivery and ..... 1532(E), 1603
sickle trait polymerization causing RBC filter failures 1466
very low postoperative levels 812
HBsAg
Comparison with HBV NAT in Japan ..... 660(L)
negative donors. with anti-HBc-positivity, HBV DNA in ..... 1616(L)
pretransfusion screening, HBV infection and 1592
prevalence/incidence in blood donors ..... 966(E), 975
HBV
carriers, screening for 1592
mathematical modeling of transmission risk 537
residual risk ..... 966(E), 980, 995
transfusion-transmitted infections, in endemic area 1592
HBV NAT
and anti-HBC testing 869
efficacy of in testing pooled samples ..... 660(L)
high-throughput detection system 100
regulatory policy 1230
in serum of HBsAg-negative anti-HBc-positive donors ..... 1616(L)
stabilization methods 409
HCV
blood screening specificity/sensitivity ..... 505(L), 876
DNA and RNA high-throughput detection system 100
four-year survival of transfusion recipients and 691
with HIV NAT minipool screening 792
NAT 1230
nosocomial infection detected by NAT of blood donor 759
nucleic acid stabilization methods 409
prevalence/incidence in blood donors ..... 966(E), 975
residual risk ..... 966(E), 980, 989, 995
risk modeling in Australian donors 1365
screening, for blood transfusion recipients 1501
transfusion-related infection, lookback program in England 1146
transmission risk, mathematical modeling 537
yield after NAT screening 862
HCV core antigen detection
by automated chemiluminescent immunoassay 349
comparison of immunoblot assays for 1053
in early infection phase ..... 505(L), 1037
before seroconversion ..... 505(L), 1032
HCV RNA
comparative yield of EIA and ELISA 1507
high-throughput detection system 100
Procleix HIV-1/HCV multiplex assay ..... 1525(L)
quantification before seroconversion 1032
screening assay, sensitivity of 527
sensitivity in early infection phase 1037
specificity of screening 876
Hematochromatosis, female blood donors and 798
Hematopoietic malignancy transmission risk, in HPC transplantation 495
Hematopoietic recovery, composition of leukapheresis components and 1159
Hematopoietic stem cells, see also HPC(s)
adult, plasticity of 1096
expansion, using AB serum and bFGF 921
transplantation, risk for heritable malignancy transmission 495
Hemolysis, transfusion-associated
after delayed hemolytic transfusion reaction 1086
after minor ABO-mismatching 1293
caused by donor anti-Jk^a in liver transplant recipient 363
in infants with T-activated RBCs 1428
in neonatal intensive care population 1428
posttransplant immune-mediated 198
Hemolytic anemia, microangiopathic due to mitral valve 1105
Hemolytic uremic syndrome ..... 387, 388(E)
Hemophilia with inhibitors, rFVIIa for 114
Hemorrhage
fetomaternal hemorrhage 947, 1067
postoperative, rFVIIa for 114
Hemostasis, hetastarch *vs.* pentastarch 27
Hemovigilance systems ..... 1249(E), 1356
Hepatitis, posttransfusion 100
Hetastarch, hemostatic effects *vs.* pentastarch 27
Hexanol, effect on stored RBCs 830
High-throughput detection system, for HBV DNA and HCV RNA 100
Historical perspective, George Washington 275
HIV
blood screening specificity/sensitivity 876
EIA specificity for HIV antibodies 1046
with HCV NAT minipool screening 792
inactivation in blood 1308
NAT 1230
nucleic acid stabilization methods 409
perceived risk from blood donation 679
prevalence/incidence in blood donors ..... 966(E), 975
Procleix HIV-1/HCV multiplex assay ..... 1525(L)
residual risk in Spain 995
residual risk of ..... 966(E), 980, 989
risk modeling in Australian donors 1365
RNA blood screening assay, sensitivity of 527
seroconverting donors, delayed return of 414
specificity/sensitivity of screening 876
transfusion trigger for 456
transmission risk, mathematical modeling 537
WBC-reduced RBCs *vs.* non-WBC-reduced RBCs for 265
yield after NAT screening 862
HLA antibodies
class II, associated with TRALI ..... 1102(L)
efficacy of WBC reduction in neonates 159
pretreatment for RBC adherence assay detection 476
HLA-C antigen mismatch, platelet transfusion refractoriness 302
Holley antigen 52
Hospital care costs, impact of WBC reduction on ..... 1106(E), 1123
HPC mobilization. *See* Granulocyte mobilization
HPC
cryopreservation with high cell count ..... 962(L)
transplantation, granulocyte transfusions for infections in ..... 1393(E), 1414
HTLV
diagnostic strategies 780
prevalence/incidence in blood donors ..... 966(E), 975
residual risk of ..... 966(E), 980
Human neutrophil antigens
in Japanese population 651
in northern Germany and Uganda populations 469
nomenclature ..... 393(E), 469, 1396(E), 1523(L)
Human plasma derivatives, enhancing safety of ..... 973(E), 999, 1005, 1011
Human platelet antigens
frequency distribution of antigens in 317
genotyping, with simultaneous PCR 1089
Human polymerized Hb solution, for acute chest syndrome 1422
Human serum albumin pasteurization, parvovirus B19 inactivation during ..... 973(E), 1011
Hypocalcemia treatment, during PBPC harvesting 1340
Hypomagnesemia, induced by plasma exchange in liver failure patients and 1598
Hypotension
posttransfusion, WBC reduction and 265
prevention, IV fluids in autologous blood donors 226
during staphylococcal protein A column therapy 1458

I

IgG
quantification 612
RBC-bound, in visceral leishmaniasis 1442
solutions, parvovirus and enterovirus removal from ..... 973(E), 1005
IL-3, ex vivo expansion of progenitor cells 581

IL-10, ex vivo expansion of progenitor cells 581
Immune globulin preparation
pediatric transfusion guidelines 1398
prion protein removal from ..... 973(E), 999
Immunoblot assay, *Babesia microti* antibody detection 1488
Immunofluorescent antibody test, with ELISA, for
malaria detection 357
Immunomagnetic cell selection
for chronic lymphoproliferative disorders 912
in closed-bag system for cord blood transplant 1285
Immunomodulation, for WBC reduction in neonates 159
Immunoprophylaxis, for D– patients receiving platelet transfusions
from D+ donors ..... 136(E), 173, 177, 1618
Immunosuppression, hemolyisis after minor
ABO-mismatched PBPC transplant 1293
Immunosuppressive transfusion effect, apoptosis, transforming growth
factor-β and 1221
Inab phenotype, acquired 1448
Inappropriate transfusion, interventions for 1224
Incidence rate/window period model, international
application ..... 966(E), 975, 980, 989, 994
India, HPA-1 system frequency analysis 317
Infants. *See also* Neonates
DPT vaccination as trigger for autoimmune
hemolytic anemia 567
premature, transmission of WA1-type *Babesia* 1482
Infections
in HPC transplantation, granulocyte transfusions
for ..... 1393(E), 1414
nosocomial 159, 759
postoperative wound, allogeneic plasma exposure and 107
Infusable-grade L15 medium 433
In-line filter collection system, for before-storage WBC reduction 734
Interlaboratory variation, UK National External Quality Assessment
Scheme gating and standardization strategy for 738
Intraoperative blood salvage 451
Ionized calcium, stabilization during PBPC harvesting 1340
Ireland, HCV screening for blood transfusion recipients 1501
Iron
balance, maintaining in female blood donors 798
deficiency anemia, in female blood donors 798
depletion, after blood donation ..... 664(E), 799
dextran therapy and pseudohemolysis 135
low, cardiovascular risk and 1135
replacement, for female blood donors 798
Irradiated RBCs, elastic properties of 1196
Isoimmunization, against CD36 1173
Israel, Lu:6 phenotype in 247
Italy, residual risk of HCV and HIV infections ..... 966(E), 989
IV fluids in autologous blood donors 226

J

Japanese population, HNA-2a expression 651
Jaundice, neonatal 44
Joseph antigen 52

K

Kala-azar 1442
Knops blood group system 251

L

Leishmania donovani, transfusion transmission in dogs ..... 381(L)
Lenograstim 928
Lesion of collection 343
Leukapheresis
citrate and calcium effects in 935
component composition, hematopoietic recovery and 1159
lenograstim with dexamethasone for 928
microbial contamination and 10
Leukostasis, with cerebrovascular nodules 965
Leukocytosis 663
Light-chain shuffling 59
Line immunoassay, for HTLV-I and HTLV-II diagnosis 780
Liver disease outcome, for spinal surgery transfusions 183
Liver failure, plasma exchange-induced hypomagnesemia 1598
Liver transplant recipient, hemolysis caused by donor anti-Jk^a 363
Long-term culture initiating cells, ex vivo expansion of 581
Lookback program
anti-HCV screening 1501
HCV and HIV-1 yield after NAT screening 862
probability of HCV testing 1140
Lutheran blood group system 247
Lymhoblastic leukemia, leukocytosis in 663
Lymphoproliferative disorders, immunomagnetic purging strategy 912

M

Magnesium
effect on platelet storage in additive solutions 76
plasma exchange in liver failure patients and 1598
Malaria, combined antibody and antigen screening 357
Malignancy, outcome for spinal surgery transfusions 183
Marrow
race/ethnicity of donors *vs.* cord blood donors ..... 1246(E), 1279
stromal cells cultured with AB serum-based medium for stem
cell expansion 921
Maternofetal transfusion, detected by gel-based typing 1531
Mathematical modeling
of HBV, HCV and HIV transmission risk 537
of intraoperative blood salvage 451
Matrix metalloproteinase-9, elevation during HPC mobilization
by G-CSF 588
McLeod phenotype ns 287
McLeod syndrome ..... 284(E), 287
Medical factors, in blood donation 669
Metastatic melanoma, autologous monocyte collection for dendritic cell
vaccination therapy 428
Methotrexate, minor ABO-mismatched PBPC transplant,
hemolysis after 1293
Microbial contamination, of PBPCs 10
Microthrombi, presence in organs in thrombotic thrombocytopenic
purpura 387
Mitral valve-induced microangiopathic hemolytic anemia 1105
MoAb preparation of higher affinity human D 59
Mobilization. *See also* G-CSF granulocyte mobilization
chemotherapy-induced, predictive value of circling
immature cells for PBPC collection 1514
composition of leukapheresis components, hematopoietic
recovery and 1159
Molecular studies, integrating with clinical studies ..... 284(E), 287
Monocytes, autologous collection for dendritic cell
vaccination therapy 428
Morbidity/mortality, postoperative Hb levels and 812
Mother-to-infant transmission, of TT virus infection 892
Multiple myeloma engraftment, ABO mismatch and 205
Multiply-transfused patients, DNA genotyping 232
Munchausen syndrome, in unexplained anemia 1610
Murine GVHD, PEN110 inhibition of 1326

N

Nanofiltration, for parvovirus and enterovirus removal ..... 973(E), 1005
Necrosis, due to essential thrombocythemia 1245
Necrotizing enterocolitis, T variant activation of RBCs in 1428
Neonatal alloimmune thrombocytopenic purpura, frequency
analysis 317
Neonates
efficacy of WBC reduction in 159
isoimmune thrombocytopenia, CD36 isoimmunization 1173
jaundice, warm-reactive autoantibody development in 44
transfusion-associated hemolysis with T-activated RBCs 1428
Neutrophil-specific antigens,
nomenclature ..... 393(E), 1396(E)
Nitric oxide
in RBCs ..... 1532(E), 1603
transport/delivery of ..... 1532(E), 1603

Nonhemolytic transfusion reactions, anaphylactic 766
Nonmyeloablative conditioning, multiple myeloma
  engraftment and 205
NOR polyagglutination ..... 806(L)
Nosocomial infections
    HCV, detected by donor blood NAT 759
    WBC reduction in neonates and 159
Nucleic acid testing
    anti-HBc and HBV 869
    of blood and plasma donations 1230
    of DTI phenotype 481
    HAV 1230
    high-throughput detection system for HBV and HCV 100
    HIV and HCV minipool screening 792
    pooled, benefits of ..... 966(E), 975
    reduction of residual risk ..... 966(E), 980
    for risk modeling of Australian donors 1365
    RNA stabilizing solution for 409
NucliSens Extractor 792

O

Obituary
    Louis K. Diamond 1381
    Ruth Sanger 125
Orthopedic surgery salvaged blood, detection/removal of fat
  particles in 66
Outcome
    ABO-nonidentical platelet transfusions ..... 166, 1527(L)
    of anti-HCV screening 1501
    postoperative Hb levels and 812
    predictors, for spinal surgery transfusions 183

P

p phenotype 48
Parental health history, in cord blood banking ..... 1246(E), 1275
Partial thromboplastin time, hetastarch *vs.* pentastarch 27
Parvovirus B19
    inactivation during HSA pasteurization ..... 973(E), 1011
    nucleic acid testing 1230
    presence of giant pronormoblasts in 1
    removal by nanofiltration ..... 973(E), 1005
    transmission via heat-treated clotting factor concentrates 1473
Paternal *RHD* zygosity assignment 645
PBPC collection
    allogeneic, citrate and calcium effects in 935
    CD34+ cell concentration in 904
    CD34+ cell enumeration, predictive value of 1514
    hypocalcemia treatment during 1340
    influencing factors in 4
    predictive value of circulating immature cell counts 1514
PBPC components, contamination of 10
PBPC transfusion
    hematopoietic recovery, composition of leukapheresis
      components and 1159
    minor ABO-mismatch, hemolysis after 1293
PCR. *See also* RT-PCR
    Babesia microti antibody detection 1488
    for HBV and anti-HBc NAT 869
    for HTLV-I and HTLV-II diagnosis 780
    posttransfusion hepatitis 100
    quantitation of CMV in RBC units 403
    quantitation of residual WBCs in filtered blood 87
    for *RHD* zygosity assignment 645
    with simultaneous genotyping of HPA-1 and HPA-13w 1089
    Treponema pallidum 94
Pediatric blood transfusions
    guidelines for ..... 666(E), 754, 1398
    transmission of WA1-type *Babesia* 1482
Pediatric platelet transfusions
    D-incompatible, absence of D alloimmunization in 177
    efficacy of plasma removal and WBC reduction for 753
    guidelines for ..... 666(E), 754, 1398
PEN110
    inactivation of HIV-1 in blood 1308
    inhibition of murine GVHD 1326
    for pathogen-inactivated RBC preparation 139
    pathogen-inactivated RBCs, phase I clinical studies 146
    vs. gamma irradiation for WBC reduction 1318
Pentastarch hemostatic effects, *vs.* hetastarch 27
Peripheral blood progenitor cells. *See* PBPC(s)
pH, RBC damage during blood collection and 343
pH reagent strip, detection of bacteria in platelet concentrates 1027
Pharmacokinetic analysis, F IX concentrates 190
Phase display selection, in higher affinity human D
  MoAb preparation 59
Phenotype-matched transfusions, in sickle cell disease 684
Philippine genetic database, motherless cases 954
Photodynamic treatment, dipyridamole for protection of
  RBCs during 728
Pigs, RBC and platelet α-galactosyl expression ..... 1111(E), 1184
P^k synthase gene, null mutations of 48
Plasma donations, NAT 1230
Plasma exchange
    serum magnesium in liver failure patients and 1598
    for thrombotic thrombocytopenic purpura, predicting
      response to 572
Plasma removal
    efficacy in reducing acute reactions 556
    for pediatric platelet transfusions 753
Plasmodium falciparum, combined antibody and
  antigen screening 357
Plasticity, of adult hematopoietic stem cells 1096
Plasticizers, effect on stored RBCs 830
Platelet activation
    storage solutions and 719
    in vivo binding to WBCs after transfusion 1373
Platelet additive solution, effects on magnesium and/or potassium 76
Platelet alloantigens, processing/presentation of 958
Platelet concentrates
    bacterial contamination of ..... 380(L)
    binding of activated platelets to WBCs after transfusion 1373
    clinical assessment ..... 809(E), 849
    detecting bacteria by reagent strip method 1027
    plasma-removed, frequency of acute reactions and 556
    single-donor and sepsis risk ..... 506(L)
    ultrastructural changes and activation differences in 719
    universal bacterial culturing of 855
    in vivo viability in rabbit model 711
    WBC-reduced, autologous transfusion recovery after 1333
Platelet count recovery prediction, reticulated platelets and 368
Platelet donors, QT_c prolongation in 899
Platelet thrombopoietin receptors, in plasma
  thrombopoietin regulation ..... 279(E), 321
Platelet transfusion
    ABO-nonidentical for cardiovascular surgery
      patients ..... 166, 1527(L)
    D-incompatible ..... 136(E), 173, 177, 1618
    outcome prediction 309
    pediatric, guidelines for ..... 666(E), 754, 1398
    refractoriness 302, 309
    thrombotic thrombocytopenic purpura and ..... 1384(L)
Plateletpheresis
    FFP as by-product of 81
    procedures, comparison of 375
    QT_c prolongation in 899
Platelets
    activated, binding to WBCs in vivo after transfusion 1373
    automated culture of 774
    fresh and preserved for aspirin-induced thrombocytopathy ... 1206
    porcine α-galactosyl expression ..... 1111(E), 1184
    storage in additive solutions 76
Platelet-specific antibodies, treatment for RBC adherence
  assay detection 476
Pneumonia, postoperative 107
Point mutations, causing McLeod phenotype ..... 284(E), 287

Policy issues, phased consent policy for cord blood donation ..... 1246(E), 1268
PolyHeme, for acute chest syndrome 1422
Postoperative infection
allogeneic plasma exposure and 107
rates, WBC reduction and ..... 1106(E), 1127
Posttransplant immune-mediated hemolysis 198
Potassium, effect on platelet storage in additive solutions 76
Premature infant, transmission of WA1-type *Babesia* 1482
Primates, bovine spongiform encephalopathy transmission ..... 509(E), 513
Prion protein
endothelial expression of ..... 334, 509(E), 513, 517
expression, comparative analysis of 517
removal, by size-exclusion filter ..... 973(E), 999
removal during purification of human proteins 1497
Procleix HIV-1/HCV multiplex assay ..... 1525(L)
Progenitor cells, ex vivo expansion of 581
Protein purification, prion removal during 1497
Protein S viability, in thawed S/D-treated plasma 1581
Prothrombin time, hetastarch *vs.* pentastarch 27
p-selectin, in apheresis platelets 375
P-selectin glycoprotein ligand-1, G-CSF down modulation of 328
Psoralen plus UV-treated FFP, in vivo coagulation response 1302
Pseudohemolysis with iron dextran therapy 135

Q

QT_c prolongation, in platelet donors 899
Quality control
Fourth International Granulocyte Immunology Workshop 462
statistical process control model for WBC reduction 1059
Quality of life, transfusion trigger for HIV-infected patients 456

R

Rabbit model
RBC stroma absorption, anti-Vel reactivity and 1180
in vivo platelet concentrate viability 711
Race
blood donation and 669
of cord blood donors ..... 1246(E), 1279
D(C)(e) haplotypes in white population 627
outcome for spinal surgery transfusions 183
Randomized controlled trial
crossover, IV fluids in autologous blood donors 226
efficacy of WBC reduction for neonates 159
reactions to prestorage WBC-reduced platelets 556
universal WBC reduction ..... 1106(E), 1114, 1123, 1127
RBC adherence assays, enzyme usage in 476
RBC ATP, Erythro-Sol 2 and 824
RBC autoantibodies
in severe neonatal jaundice 44
in sickle cell disease 37
RBC solution dimethylmethylene blue phototreatment, flow-cell system for 1200
RBC units
CMV quantitation by real-time PCR 403
pathogen-inactivated concentrates, PEN110 studies 139, 146
PEN110 treatment *vs.* gamma irradiation 1318
prestorage WBC filtration 153
storage, Erythro-Sol 2 for 824
storage bag plasticizer effects on 830
RBCs
2,3-DPG levels, alkaline conditions and 747
immunologic properties of after A-zyme treatment ..... 662(C)
inactivation of HIV-1 in 1308
injury during collection, effect of anticoagulant and blood pH on 343
irradiated, elastic properties of 1196
lacking RhAG protein ..... 383(L)
nitric oxide in ..... 1532(E), 1603
porcine α-galactosyl expression ..... 1111(E), 1184
preservation with fructose diphosphate ..... 384(L)
protection during photodynamic treatment, dipyridamole for 728
T activation in neonatal intensive care population 1428
transfused
efficacy of WBC reduction for neonates 159
WBC-reduced and postoperative infection rates ..... 1106(E), 1127
Reagent strip method, for detecting bacteria in platelet concentrates 1027
Recipients
four-year survival of 691
HCV screening for 1501
Recombinant FVIIa 114
Refractory autoimmune hemolysis, staphylococcal protein A immunoadsorption 1217
Reliability, of ABO bedside testing 1348
Religion, blood transfusion refusal 812
Residual risk of transfusion-transmitted viral infection ..... 966(E), 975, 980, 989, 995, 1365
Reticulated platelets, platelet count recovery prediction and 368
Review of literature, interventions for inappropriate transfusion 1224
RFLP analysis, for *RHD* zygosity assignment 645
R168G polymorphism, variant A phenotype from 294
Rh blood group system
anti-D absence of after D-incompatible platelet transfusion ..... 136(E), 173, 177, 1618(C)
D(C)(e) haplotypes in white population 627
fetomaternal hemorrhage, semiautomated flow cytometric analysis of 1067
gel-based typing detection of maternofetal transfusion 1531
genotyping in different ethnic groups 634
immunoprophylaxis for D– patients after receiving D+ platelet transfusion donors ..... 136(E), 173, 177, 1618(C)
mutation in *RhAG* ..... 383(L)
noninvasive fetal *RHD* genotyping 1079
novel partial D phenotype 481
paternal *RHD* zygosity assignment 645
UV-visible spectrophotometric approach for typing 619
rHuG-CSF dosing schedule, CD34+ cell collection and 4
Risk
benefit assessment, for Australian donors 1365
of receiving incorrect transfusion in Germany ..... 1238(L)
RNA detection
HBV and HCV 100
Treponema pallidum 94
RNAlater method, for NAT 409
Rodents, prion protein expression ..... 509(E), 517
Ruminants, prion protein expression ..... 509(E), 517

S

Sanger, Ruth, obituary 125
SCF, ex vivo expansion of progenitor cells 581
SCN elution, EIA specificity for HIV antibodies and 1046
S/D-treated plasma, therapeutic effect after thawing 1581
Sensitivity, comparison of two anti-HCV immunoblot assays 1053
Sepsis risk and single-donor platelets ..... 506(L)
September 11, 2001 disaster
donor viral marker rates before/after ..... 1240(L)
New York blood supply and ..... 1385(L)
Serology, dimeric F(ab) 257
Shipping, of frozen blood components on dry ice 836
SI^{a-} subdivision of 251
Sickle cell disease
acute chest syndrome, PolyHeme for 1422
Hb polymerization causing RBC filter failures 1466
multiply-transfused patients, DNA genotyping for 232
patients, recommended practices in ..... 658(L)
phenotype-matched transfusions in 684
RBC alloantibodies and autoantibodies in 37
Simian foamy virus infection, in blood donor 886
Single point mutation, novel *cis AB* allele derived from 239
Single-donor platelets
absence of D alloimmunization in D-incompatible transfusions 177
collection of FFP as by-product of plateletpheresis 81
seven-day storage of 847
Size-exclusion filter, prion protein removal ..... 973(E), 999
Sociodemographic factors, in blood donation 669

Soft-shell filters, for prestorage WBC filtration of RBC units 153
Solid-phase RBC adherence assays, enzyme use in 476
Specific-sequence primers, PCR with simultaneous genotyping of human platelet antigens 1089
Spectrophotometric blood typing 619
Spinal surgery, outcome predictors for 183
Spongiform encephalopathy, prion protein removal from immune globulin preparation ..... 973(E), 999
Standardization, strategy for WBC counting 738
Staphylococcal protein A column therapy 1217, 1458
Statistical process control model, for WBC reduction 1059
Sterility testing, of peripheral blood cellular components 10
Stomatocytosis in Japanese family with Rh_{mod} phenotype ..... 383(L)
Storage
  alkaline solutions, 2,3-DPG preservation and 747
  of cord blood ..... 1383(L)
  improvement with Erythro-Sol 2 824
  plasticizers in storage bags and 830
  platelet additive solution, effects on magnesium and/or potassium 76
  of RBC units, prestorage WBC filtration and 153
  of single-donor platelets 847
  solutions, platelet ultrastructural changes and 719
Surgery
  ABO-nonidentical platelet transfusions for ..... 166, 1527(L)
  allogeneic plasma exposure, infection risk and 107
  hospital costs, impact of WBC reduction on ..... 1106(E), 1123
  outcomes, after ABO-mismatch platelet transfusions ..... 1527(L)
  postoperative infection rates, WBC reduction and .... 1106(E), 1127
  salvaged blood, detection/removal of fat particles from 66
Survival, of transfusion recipients 691
Syphilis, PCR testing 94

T

Technicon H3 cell counter, fat particle detection in salvaged blood 66
Temperature
  blood prestorage, for *Yersinia enterocolitica* load reduction 422
  posttransfusion elevation, WBC reduction and 265
Thrombin generation impairments, rFVIIa for 114
Thrombin time, hetastarch *vs.* pentastarch 27
Thrombocythemia, essential 1245
Thrombocytopathy, fresh and preserved platelets for 1206
Thrombopoietin ..... 279(E), 321
Thrombotic thrombocytopenic purpura
  ADAMTS13 deficiency and ..... 1523(L)
  Microscopic atlas of 387
  pathogenesis, treatment and ..... 387, 388(E)
  plasma exchange response, prediction of 572
  platelet transfusion and ..... 1384(L)
Tick-borne diseases, seroprevalence in donors 1585
TRALI, associated with HLA class II antibodies ..... 1102(L)
Transforming growth factor-β, immunosuppressive transfusion effect and 1221
Transfusion errors in Germany ..... 1238(L)
Transfusion reactions
  anaphylactic 766
  hazard reporting ..... 1249(E), 1356
Transfusion trigger, for HIV-infected patients 456
Transmissible spongiform encephalopathies
  animal models ..... 334, 509(E), 513, 517
  clearance studies, hamster scrapie as model for 1497
  dissemination, cellular prion protein and 334
Transmission, transfusion-associated
  Babesia microti 1154, 1482
  of bovine spongiform encephalopathy ..... 334, 509(E), 513, 517
  West Nile virus 1019
Transplantation complications, posttransplant immune-mediated hemolysis 198
Traumatic bleeding, rFVIIa for 114
Treponema pallidum, PCR testing for 94
Trypanosoma cruzi, in blood donors 549
TT virus infection, childhood 892

U

Umbilical cord blood. *See* Cord blood
United Kingdom National External Quality Assessment Scheme 738
United States
  blood collection and transfusion in 1997 1253
  blood donor demographics, *T. cruzi* seroprevalence and 549
UV light treatment, of FFP with psoralen 1302

V

Vaginal delivery, WBC yield from cord blood units and 210
vCJD ..... 334, 509(E), 513, 517
Viral Activation Transfusion Study 265, 456
Viral infections, transfusion-related
  English HCV lookback program 1146
  residual risk of ..... 966(E), 980
  in Spain 995
Viral marker rates, of blood donors before/after Sept. 11, 2001 ..... 1240(L), 1385(L)
Visceral leishmaniasis 1442
vWF
  cleaving protease activity 572
  platelet aggregation in apheresis platelets 375

W

Warfarin treatment, FVII pharmacokinetics after 1302
Waring blender syndrome 1105
Warm autoantibodies
  prophylactic antigen-matched donor blood for 1435
  in utero development 44
Washington, George 275
WBC count
  CD34+ cell collection and 4
  daily run control with gating strategy for 738
  in filtered blood 87
WBC filters. *See* Filters
WBC reduction
  coronary artery bypass graft surgery hospital costs and ..... 1106(E), 1123
  cardiac postoperative infection rates and ..... 1106(E), 1127
  efficacy in neonates 159
  for patients with sickle cell disease ..... 658(L)
  for pediatric platelet transfusions 753
  frequency of acute reactions and 556
  pediatric guidelines 1398
  PEN110 *vs.* gamma irradiation 1318
  of platelet concentrates, autologous transfusion recovery after 1333
  prestorage 153, 734
  in RBC suspensions, dipyridamole for protection of 728
  seven-day storage of single-donor platelets and 847
  sickle Hb polymerization causing RBC filter failures 1466
  statistical process control model 1059
  temperature elevation and hypotension incidence and 265
  treatment of leukocytosis 663
  universal ..... 1106(E), 1114, 1123, 1127
  for *Yersinia enterocolitica* load reduction 422
WBC yield, from cord blood 210
West Nile virus 1019
Western blot
  HCV 1053, 1063
  HTLV-I/II 780
Whole blood
  bacterial contamination in ..... 380(L)
  before-storage WBC reduction of 734
  G-CSF-mobilized, safety profile of 433
  Procleix HIV-1/HCV multiplex assay ..... 1525(L)
Window-period donations
  HCV RNA levels in 1032
  transfusion-transmitted infection risk ..... 966(E), 975

X

Xenogeneic blood transfusion ..... 1111(E), 1184

Y

Yersinia enterocolitica, load reduction in blood 422